Ipratropium: uses, dosing, side effects & brands
Ipratropium is an anticholinergic sold in the U.S. under 3 brand and generic names, for bronchial spasm, bronchitis and pulmonary emphysema. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Anticholinergic
- Treats (across its forms)
- Bronchial Spasm, Bronchitis and Pulmonary Emphysema
- Available as
- Spray/Inhaler, metered · Solution · Spray/Inhaler
- Sold as
- 3 products — Atrovent, Atrovent Hfa and Ipratropium Bromide
- Prescription?
- Prescription only
- Generic available?
- Yes
- What the pharmacy pays
- about $0.62 per ml — not your price
How Atrovent Hfa is dosed
From the FDA label for Atrovent Hfa (application NDA021527). Other ipratropium products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The usual starting dosage of ATROVENT HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours. ATROVENT HFA is a solution aerosol that does not require shaking. However, as with any other metered-dose inhaler, some coordination is required between actuating the canister and inhaling the medication. Patients should "prime" or actuate ATROVENT HFA before using for the first time by releasing 2 test sprays into the air away from the face. In cases where the inhaler has not been used for more than 3 days, prime the inhaler again by releasing 2 test sprays into the air away from the face. Patients should avoid spraying ATROVENT HFA into their eyes. Each inhaler provides sufficient medication for 200 actuations. The inhaler should be discarded after the labeled number of actuations has been used. The amount of medication in each actuation cannot be assured after this point, even though the canister is not completely empty. Patients should be instructed on the proper use of their inhaler [ see Patient Counseling Information (17) ]. For oral inhalation only Two inhalations four times a day, not to exceed 12 inhalations in 24 hours ( 2 )
Everything below is the FDA label for Atrovent Hfa (spray/inhaler, metered). Ipratropium is also sold as solution and spray/inhaler, and those are different medicines to take — follow the label for the one you were prescribed.
Atrovent Hfa side effects
The following adverse reactions are described, or described in greater detail, in other sections: Hypersensitivity Reactions, Including Anaphylaxis [ see Contraindications (4) and Warnings and Precautions (5.2) ] Paradoxical Bronchospasm [ see Warnings and Precautions (5.3) ] Ocular Effects [ see Warnings and Precautions (5.4) ] Urinary Retention [ see Warnings and Precautions (5.5) ] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients. Most common adverse reactions (>5% incidence in the 12-week placebo-controlled trials) were bronchitis, COPD exacerbation, dyspnea, and headache ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience The adverse reaction information concerning ATROVENT HFA is derived from two 12-week, double-blind, parallel-group studies and one 1-year open-label, parallel group study. These studies compared ATROVENT HFA Inhalation Aerosol, ATROVENT CFC Inhalation Aerosol, and placebo (in one study only) in 1,010 COPD patients. The following table lists the incidence of adverse reactions that occurred at a rate of…
Who shouldn’t take Atrovent Hfa
ATROVENT HFA is contraindicated in the following conditions [ see Warnings and Precautions (5.2) ]. Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) Hypersensitivity to atropine or any of its derivatives ( 4 )
Atrovent Hfa drug interactions
ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT HFA and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) 7.1 Anticholinergic Agents There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of ATROVENT HFA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [ see Warnings and Precautions (5.4 , 5.5) ].
Every ipratropium product we track (3)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Spray/Inhaler | Generic | $1 | View → | |
| 2 | 72/100 | Prescription | Spray/Inhaler | Generic | $1 | View → | |
| 3 | 70/100 | Prescription | Solution | Generic | $1 | View → |
Combination products containing ipratropium
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
Ipratropium recalls
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
How long ipratropium keeps
No ipratropium label we read sets a separate limit for after opening, but they do specify how it must be stored — and the stability behind any date assumes those conditions.
Does ipratropium expire? The in-use limits and storage rules from its labelsIpratropium and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for ipratropium: levels in milk, effects in breastfed infants, and the drugs it would consider insteadAlthough no published data exist on the use of ipratropium, its use produces negligible maternal serum levels and any drug in breastmilk would not be absorbed by the infant. The risk to the breastfed infant of maternal ipratropium inhalation is small. Breastfeeding can be continued during ipratropium therapy.
National Institute of Child Health and Human Development, record revised January 15, 2026. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about ipratropium
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 20,404 reports naming ipratropium, and the FDA flagged 71% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dyspnoea2,747 reports
- pneumonia1,517 reports
- cough1,321 reports
- fatigue1,153 reports
- asthma1,119 reports
- nausea1,109 reports
- headache919 reports
- chronic obstructive pulmonary disease866 reports
Read these as a signal, not a rate. A report does not mean ipratropium caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is Atrovent Hfa?
Atrovent Hfa (Ipratropium Bromide) is an anticholinergic used to treat Bronchial Spasm, Bronchitis, Pulmonary Emphysema, Perennial Allergic Rhinitis.
What kind of drug is ipratropium?
The FDA classifies ipratropium as an anticholinergic. Anticholinergic drugs block acetylcholine, the chemical messenger of the body's "rest and digest" nervous system, by occupying its muscarinic receptors. This eases muscle spasms, dries up secretions, relaxes the bladder and airways, and speeds the heart, depending on the tissue. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take ipratropium with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run ipratropium against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is ipratropium sold under?
We track 3 ipratropium-containing products in the U.S.: Atrovent, Atrovent Hfa and Ipratropium Bromide. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does ipratropium come in?
Across the brands we track, ipratropium is currently marketed as spray/inhaler, metered, solution and spray/inhaler, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic ipratropium?
Yes. Our catalog lists 1 generic ipratropium product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
Has ipratropium been recalled?
The FDA's Enforcement database lists 1 recall record whose product description mentions ipratropium. The most recent: Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP (Mar 26, 2024). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.
Cite this page
- APA
- pharmaranks. (2026, July 24). Ipratropium: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/ipratropium
- MLA
- “Ipratropium: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/ipratropium.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for ipratropium on DailyMed (NIH) ↗.